Rachel Sigler
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Rachel Sigler has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Saima Aslam
Division of Infectious Diseases and Global Public Health, University of California, San Diego, La Jolla, California, USA
5 shared publications Ajay Bharti
Division of Transplant and Hepatobiliary Surgery Department of Surgery University of California, San Diego San Diego California USA
1 shared publicationAlbert Eid
Division of Infectious Diseases Department of Internal Medicine University of Kansas Medical Center Kansas City Kansas USA
1 shared publicationAtikur Rahman
Department of Biostatistics & Data Science University of Kansas Medical Center Kansas City Kansas USA
1 shared publicationBenjamin Chen
Division of Infectious Disease and Global Public Health Department of Medicine University of California, San Diego San Diego California USA
1 shared publication- Cameron R. Wolfe
Division of Infectious Diseases Duke University Medical Center Durham North Carolina USA
1 shared publication
Latest Publications
- 21 May 2026
- Published by Wiley in Transplant Infectious Disease
- Vol. 28 (4) , e70243
Possible Donor‐Derived Tuberculosis in an Orthotopic Heart Transplant Recipient
- 21 May 2026
- Published by Wiley in Transplant Infectious Disease
- Vol. 28 (4) , e70243
Possible Donor‐Derived Tuberculosis in an Orthotopic Heart Transplant Recipient
- Open Access
- 6 May 2026
- Published by Wiley in Transplant Infectious Disease
- Vol. 28 (4) , e70231
Epidemiology and Outcomes of Cryptococcal Infections in Liver Transplant Recipients: A Retrospective Cohort Study at a US Academic Center
Background: Cryptococcal infections in solid organ transplant (SOT) are relatively uncommon posttransplant, but carry significant morbidity and mortality. SOT represents a significant proportion of cryptococcosis among immunocompromised patients. Data specific to liver transplant recipients remains limited. Methods: We performed a retrospective cohort study of 346 liver transplant recipients at a US academic center to identify predictors and outcomes associated with cryptococcal infection. Associations between infection and clinical variables were analyzed. Univariate logistic regression was performed to estimate odds ratios (OR) and 95% confidence intervals (CI). Results: Twelve patients (3.6%) developed cryptococcosis within 1 year of liver transplant. Significant differences between infected and noninfected patients were observed for maintenance immunosuppression ( p < 0.001), infectious comorbidities ( p = 0.007), and treatment of rejection ( p = 0.041). Patients residing in rural ZIP codes had a significantly higher risk of cryptococcal infection, whereas residing in urban ZIP codes was found to be protective (OR 0.305; 95% CI 0.095–0.985; p = 0.047). Longer waitlist duration also increased infection risk at 0.01% per day ( p = 0.017). Among infected patients, very early infection (< 45 days posttransplant) was associated with shorter median survival (382 days) compared with early (45–180 days posttransplant, median1462 days survival) and late (> 180 days posttransplant, median 1641 days survival) infection ( p = 0.09). Conclusions: Cryptococcal infection after liver transplantation is rare but linked to immunosuppression patterns and geographic risk factors. Recipients from rural ZIP codes may face increased environmental exposure or healthcare access barriers, contributing to elevated risk. Multicenter studies are warranted to identify modifiable risk factors and guide antifungal prophylaxis and screening strategies.
- 6 May 2026
- Published by Wiley in Transplant Infectious Disease
- Vol. 28 (4) , e70231
Open AccessEpidemiology and Outcomes of Cryptococcal Infections in Liver Transplant Recipients: A Retrospective Cohort Study at a US Academic Center
Background: Cryptococcal infections in solid organ transplant (SOT) are relatively uncommon posttransplant, but carry significant morbidity and mortality. SOT represents a significant proportion of cryptococcosis among immunocompromised patients. Data specific to liver transplant recipients remains limited. Methods: We performed a retrospective cohort study of 346 liver transplant recipients at a US academic center to identify predictors and outcomes associated with cryptococcal infection. Associations between infection and clinical variables were analyzed. Univariate logistic regression was performed to estimate odds ratios (OR) and 95% confidence intervals (CI). Results: Twelve patients (3.6%) developed cryptococcosis within 1 year of liver transplant. Significant differences between infected and noninfected patients were observed for maintenance immunosuppression ( p < 0.001), infectious comorbidities ( p = 0.007), and treatment of rejection ( p = 0.041). Patients residing in rural ZIP codes had a significantly higher risk of cryptococcal infection, whereas residing in urban ZIP codes was found to be protective (OR 0.305; 95% CI 0.095–0.985; p = 0.047). Longer waitlist duration also increased infection risk at 0.01% per day ( p = 0.017). Among infected patients, very early infection (< 45 days posttransplant) was associated with shorter median survival (382 days) compared with early (45–180 days posttransplant, median1462 days survival) and late (> 180 days posttransplant, median 1641 days survival) infection ( p = 0.09). Conclusions: Cryptococcal infection after liver transplantation is rare but linked to immunosuppression patterns and geographic risk factors. Recipients from rural ZIP codes may face increased environmental exposure or healthcare access barriers, contributing to elevated risk. Multicenter studies are warranted to identify modifiable risk factors and guide antifungal prophylaxis and screening strategies.
- 8 November 2023
- Published by Wiley in Transplant Infectious Disease
- Vol. 25 (6) , e14172
“They paged me what?”: A transplant infectious disease guide to donor calls
Donor‐derived infections in solid organ transplantation can be prevented by risk stratification of donors based on available information, and inquiries surrounding possible or diagnosed infection are common questions posed to transplant infectious disease subspecialists. This article outlines the five key steps in addressing a donor call from a transplant team in a systematic approach, focusing on donor and recipient‐specific factors, transmissibility and treatment of possible infections, and the likelihood of a patient's future organ offers and mortality remaining on the waitlist. These principles are then applied to five donor call cases, in which we review the key takeaway points and supporting literature. These cases can be used as a resource for teaching with trainees. image
- 8 November 2023
- Published by Wiley in Transplant Infectious Disease
- Vol. 25 (6) , e14172
“They paged me what?”: A transplant infectious disease guide to donor calls
Donor‐derived infections in solid organ transplantation can be prevented by risk stratification of donors based on available information, and inquiries surrounding possible or diagnosed infection are common questions posed to transplant infectious disease subspecialists. This article outlines the five key steps in addressing a donor call from a transplant team in a systematic approach, focusing on donor and recipient‐specific factors, transmissibility and treatment of possible infections, and the likelihood of a patient's future organ offers and mortality remaining on the waitlist. These principles are then applied to five donor call cases, in which we review the key takeaway points and supporting literature. These cases can be used as a resource for teaching with trainees. image
- 3 November 2023
- Published by Wiley in Transplant Infectious Disease
- Vol. 25 (6) , e14167
Post‐acute sequelae of COVID‐19 in solid organ transplant recipients
Background: Post‐acute sequelae of coronavirus disease 2019 (COVID‐19) (PASC), defined as prolonged symptoms following an episode of COVID‐19, is not well‐characterized in solid organ transplant recipients (SOTR). In this study, we aimed to assess the prevalence of PASC in SOTR, its descriptive characteristics, and associated risk factors.Methods: We retrospectively identified SOTRs with acute COVID‐19 between June 1, 2020 and April 15, 2022, and abstracted demographic and medical history, characteristics of acute COVID‐19 illness, and COVID‐19 vaccination status. We defined PASC as ongoing/new symptoms present at 6 weeks or longer following acute COVID‐19 diagnosis.Results: Among 208 SOTRs with acute COVID‐19, 72 (35%) developed PASC. Common symptoms were respiratory symptoms (67%), headache (40%), and difficulty concentrating (10%). Severe acute COVID‐19 disease and presence of respiratory symptoms were associated with higher odds of PASC in multivariable analyses, while receipt of at least one COVID‐19 vaccination prior to transplantation was protective.Conclusion: We found that PASC occurs in about a third of SOTRs with acute COVID‐19 and has similar symptoms as described previously in immunocompetent hosts. Pre‐transplant vaccination may be protective. Further prospective multicenter studies are needed. image
- 3 November 2023
- Published by Wiley in Transplant Infectious Disease
- Vol. 25 (6) , e14167
Post‐acute sequelae of COVID‐19 in solid organ transplant recipients
Background: Post‐acute sequelae of coronavirus disease 2019 (COVID‐19) (PASC), defined as prolonged symptoms following an episode of COVID‐19, is not well‐characterized in solid organ transplant recipients (SOTR). In this study, we aimed to assess the prevalence of PASC in SOTR, its descriptive characteristics, and associated risk factors.Methods: We retrospectively identified SOTRs with acute COVID‐19 between June 1, 2020 and April 15, 2022, and abstracted demographic and medical history, characteristics of acute COVID‐19 illness, and COVID‐19 vaccination status. We defined PASC as ongoing/new symptoms present at 6 weeks or longer following acute COVID‐19 diagnosis.Results: Among 208 SOTRs with acute COVID‐19, 72 (35%) developed PASC. Common symptoms were respiratory symptoms (67%), headache (40%), and difficulty concentrating (10%). Severe acute COVID‐19 disease and presence of respiratory symptoms were associated with higher odds of PASC in multivariable analyses, while receipt of at least one COVID‐19 vaccination prior to transplantation was protective.Conclusion: We found that PASC occurs in about a third of SOTRs with acute COVID‐19 and has similar symptoms as described previously in immunocompetent hosts. Pre‐transplant vaccination may be protective. Further prospective multicenter studies are needed. image
- Open Access
- 9 March 2022
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 9 (5) , ofac120
Evaluation of an Infectious Diseases Elective for Early Clinical Medical Students on Their Internal Medicine Clerkship
Background: Early medical subspecialty training is an emerging trend in medical education. These electives are still rare for Early Clinical Medical Students (ECMS). We describe the introduction of an Infectious Disease (ID) inpatient consult rotation elective for ECMS. Methods: In addition to seeing patients and rounding with the inpatient ID consult team, we created a supplemental curriculum to provide added support for ECMS that included a checklist of clinical skills learning objectives, self-directed, publicly available mini-lectures on ID topics, and an ID Coach who provided directed and personalized tutoring for students. We surveyed ECMS, ID fellows and attendings on service, and ID Coaches to evaluate the acceptability, feasibility, and effectiveness of this rotation and curriculum. Results: The majority of ECMS reported that the rotation was a useful educational experience and that the ID Coach was one of the most valuable aspects of the rotation. The majority of ID fellows and attendings reported that working with ECMS improved their job satisfaction and well-being. Conclusions: This multifaceted approach to early medical subspecialty training was valuable for ECMS, ID fellows, and faculty. Ongoing improvements in this curriculum will provide a useful tool for medical education.
- 9 March 2022
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 9 (5) , ofac120
Open AccessEvaluation of an Infectious Diseases Elective for Early Clinical Medical Students on Their Internal Medicine Clerkship
Background: Early medical subspecialty training is an emerging trend in medical education. These electives are still rare for Early Clinical Medical Students (ECMS). We describe the introduction of an Infectious Disease (ID) inpatient consult rotation elective for ECMS. Methods: In addition to seeing patients and rounding with the inpatient ID consult team, we created a supplemental curriculum to provide added support for ECMS that included a checklist of clinical skills learning objectives, self-directed, publicly available mini-lectures on ID topics, and an ID Coach who provided directed and personalized tutoring for students. We surveyed ECMS, ID fellows and attendings on service, and ID Coaches to evaluate the acceptability, feasibility, and effectiveness of this rotation and curriculum. Results: The majority of ECMS reported that the rotation was a useful educational experience and that the ID Coach was one of the most valuable aspects of the rotation. The majority of ID fellows and attendings reported that working with ECMS improved their job satisfaction and well-being. Conclusions: This multifaceted approach to early medical subspecialty training was valuable for ECMS, ID fellows, and faculty. Ongoing improvements in this curriculum will provide a useful tool for medical education.
- Open Access
- 25 February 2022
- Published by Wiley in Transplant Infectious Disease
- Vol. 24 (2) , e13809
SARS‐CoV‐2 vaccine clinical efficacy in SOT: What we know and our current gaps
- 25 February 2022
- Published by Wiley in Transplant Infectious Disease
- Vol. 24 (2) , e13809
Open AccessSARS‐CoV‐2 vaccine clinical efficacy in SOT: What we know and our current gaps
- Open Access
- 24 February 2022
- Published by Wiley in Transplant Infectious Disease
- Vol. 24 (2) , e13788
Coronavirus disease 2019 vaccination is protective of clinical disease in solid organ transplant recipients
Background: Clinical effectiveness of coronavirus disease 2019 (COVID‐19) vaccination in solid organ transplant recipients (SOTRs) is not well documented despite multiple studies demonstrating sub‐optimal immunogenicity.Methods: We reviewed medical records of eligible SOTRs at a single center to assess vaccination status and identify cases of symptomatic COVID‐19 from January 1 to August 12, 2021. We developed a Cox proportional hazards model using the date of vaccination and time since transplantation as a time‐varying covariate with age and gender as potential time‐invariant confounders. Survival curves were created using the parameters estimated from the Cox model. Results: Among 1904 SOTRs, 1362 were fully vaccinated (96% received mRNA vaccines) and 542 were either unvaccinated (n = 470) or partially vaccinated (n = 72). There were 115 cases of COVID‐19, of which 12 occurred in fully vaccinated individuals. Cox regression with the date of vaccination and time since transplantation as the time‐varying co‐variates showed that after baseline adjustment for age and sex, being fully vaccinated had a significantly lower hazard for COVID‐19, hazard ratio (HR) = 0.29 and 95% confidence interval ([CI] 0.09, 0.91).Conclusion: We found that 2‐dose mRNA COVID‐19 vaccination was protective of symptomatic COVID‐19 in vaccinated versus unvaccinated SOTRs.Tweet: COVID‐19 vaccination was associated with a significantly lower hazard for symptomatic COVID‐19 (HR 0.29; 95% CI 0.09, 0.91) among 1904 SOT recipients at a single center from January 1 to August 12, 2021.
- 24 February 2022
- Published by Wiley in Transplant Infectious Disease
- Vol. 24 (2) , e13788
Open AccessCoronavirus disease 2019 vaccination is protective of clinical disease in solid organ transplant recipients
Background: Clinical effectiveness of coronavirus disease 2019 (COVID‐19) vaccination in solid organ transplant recipients (SOTRs) is not well documented despite multiple studies demonstrating sub‐optimal immunogenicity.Methods: We reviewed medical records of eligible SOTRs at a single center to assess vaccination status and identify cases of symptomatic COVID‐19 from January 1 to August 12, 2021. We developed a Cox proportional hazards model using the date of vaccination and time since transplantation as a time‐varying covariate with age and gender as potential time‐invariant confounders. Survival curves were created using the parameters estimated from the Cox model. Results: Among 1904 SOTRs, 1362 were fully vaccinated (96% received mRNA vaccines) and 542 were either unvaccinated (n = 470) or partially vaccinated (n = 72). There were 115 cases of COVID‐19, of which 12 occurred in fully vaccinated individuals. Cox regression with the date of vaccination and time since transplantation as the time‐varying co‐variates showed that after baseline adjustment for age and sex, being fully vaccinated had a significantly lower hazard for COVID‐19, hazard ratio (HR) = 0.29 and 95% confidence interval ([CI] 0.09, 0.91).Conclusion: We found that 2‐dose mRNA COVID‐19 vaccination was protective of symptomatic COVID‐19 in vaccinated versus unvaccinated SOTRs.Tweet: COVID‐19 vaccination was associated with a significantly lower hazard for symptomatic COVID‐19 (HR 0.29; 95% CI 0.09, 0.91) among 1904 SOT recipients at a single center from January 1 to August 12, 2021.
- 22 November 2021
- Published by Springer Nature in Current Fungal Infection Reports
- Vol. 15 (4) , 151-161
Invasive Candidiasis in Liver Transplant Recipients: A Review
- 22 November 2021
- Published by Springer Nature in Current Fungal Infection Reports
- Vol. 15 (4) , 151-161
Invasive Candidiasis in Liver Transplant Recipients: A Review
- Open Access
- 5 August 2021
- Published by Wiley in Transplant Infectious Disease
- Vol. 23 (5) , e13707
Successful heart and kidney transplantation from a deceased donor with PCR positive COVID‐19
- 5 August 2021
- Published by Wiley in Transplant Infectious Disease
- Vol. 23 (5) , e13707
Open AccessSuccessful heart and kidney transplantation from a deceased donor with PCR positive COVID‐19